hepatitis A (HAV) vaccines

ApprovedVaccine

WWashington University School of Medicine

hepatitis A (HAV) vaccines is one of 2 biologic programs targeting Immunology. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunologyActive, not recruiting

ImmunologyApproved

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Immunology

#DrugCompanyPhaseTrials

Nonavalent HPV Vaccine

XXiamen University

Approved

1 2

hepatitis A (HAV) vaccines

WWashington University School of Medicine

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedActive, not recruiting

Immunology

NCT07493460

Clinical

Trials by Indication[1]

Immunology1 trial

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

Active, not recruiting·WWashington University School of Medicine·Approved·NCT07493460·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hepatitis A (HAV) vaccines. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hepatitis A (HAV) vaccines compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hepatitis A (HAV) vaccines. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: WWashington University School of Medicine

hepatitis A (HAV) vaccines

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Immunology1 trial

References

Drug Info

Quick Facts

Related News